This invention relates to a pharmaceutical combination comprising (a) a thirdgeneration EGFR tyrosine kinase inhibitorand (b) a Raf inhibitor, particularly for use in the treatment of a cancer,particularly a lung cancer. This invention also relates to usesof such a combination for the preparation of a medicament for the treatment ofa cancer； methods of treating a cancer in a subject inneed thereof comprising administering to said subject a jointlytherapeutically effective amount of said combination； pharmaceuticalcompositions comprising such combination and commercial packages thereto.
